Targeted radiopharmaceutical therapy—specifically radioligand therapy (RLT)—represents one of the fastest-growing modalities in precision oncology. By coupling a therapeutic beta-emitting radioisotope to a targeting peptide or small molecule that binds overexpressed cell-surface receptors, RLT delivers cytotoxic ionizing radiation directly to tumor cells while sparing surrounding normal tissue.
In gastroenteropancreatic neuroendocrine tumors (GEP-NETs), somatostatin receptor (SSTR) targeting with lutetium-177 (177Lu) established a new therapeutic standard following the January 2018 FDA approval of Lutathera (lutetium Lu 177 dotatate, Advanced Accelerator Applications / Novartis, NDA 208700). For eight years, Lutathera has maintained a virtual commercial monopoly in SSTR-positive GEP-NETs.
That monopoly faces its first direct market challenge. The FDA accepted the New Drug Application (NDA) with Fast Track designation for 177Lu-edotreotide (ITM-11, developed by ITM Isotope Technologies Munich SE / ITM Radiopharma), establishing a Prescription Drug User Fee Act (PDUFA) target action date of August 28, 2026.
Grounded in pivotal evidence from the international Phase 3 COMPETE trial, 177Lu-edotreotide demonstrated statistically significant improvements in progression-free survival (PFS) and overall response rate (ORR) compared to standard-of-care everolimus in patients with progressive Grade 1 and Grade 2 SSTR-positive GEP-NETs.
This landscape report analyzes the clinical and trial evidence supporting 177Lu-edotreotide, contrasts its formulation and administration profile against Lutathera, outlines the unique radiopharmaceutical billing mechanics (HCPCS A-codes vs J-codes), and details the site-of-care and payer preparation required ahead of an August 2026 launch.
What is the scenario answer for ITM-11 vs Lutathera access landscape at a glance?
Oncology care teams, nuclear medicine directors, and PBM medical directors face critical pre-launch questions: How does 177Lu-edotreotide's COMPETE trial data compare to Lutathera's NETTER-1 baseline, is there a direct head-to-head trial, how is therapeutic radiopharmaceutical billing handled, and what operational steps must sites take prior to approval?
+-----------------------------------------------------------------------------------+
| 177Lu RADIOLIGAND THERAPY COMPARISON: ITM-11 VS LUTATHERA |
+-----------------------------------------------------------------------------------+
| Parameter | 177Lu-Edotreotide (ITM-11) | Lutathera (Lu 177 Dotatate) |
|---|---|---|
| Target / Isotope| SSTR / Beta-emitting 177Lu | SSTR / Beta-emitting 177Lu |
| Formulation | No-carrier-added (n.c.a.) 177Lu | Carrier-added 177Lu |
| Developer | ITM Radiopharma | Novartis (AAA) |
| FDA Status | Pending NDA (PDUFA Aug 28, 2026) | Approved Jan 26, 2018 (NDA 208700)|
| Pivotal Trial | COMPETE Phase 3 (NCT03049189) | NETTER-1 Phase 3 (NCT01578239)|
| Comparator | Everolimus 10mg oral daily | High-dose Octreotide LAR 60mg |
| Median PFS | 23.9 mo vs 14.1 mo (HR 0.67) | 28.4 mo vs 8.5 mo (HR 0.21) |
| Dosing Schedule | 7.5 GBq IV q3months x4 cycles | 7.4 GBq IV q8weeks x4 cycles |
| Billing Code | HCPCS A-code Pending | HCPCS A9513 ($/mCi) |
+-----------------------------------------------------------------------------------+
Direct Answer: 177Lu-edotreotide (ITM-11) is under FDA review with a PDUFA action date of August 28, 2026 for SSTR-positive GEP-NETs. The pivotal COMPETE Phase 3 trial demonstrated a median PFS of 23.9 months versus 14.1 months for oral everolimus (HR 0.67, p=0.022). It represents the first direct 177Lu/SSTR competitor to Lutathera (approved 2018; NETTER-1 mPFS 28.4 vs 8.5 months). There is no head-to-head edotreotide versus dotatate trial. Crucially for health systems and payers, therapeutic radiopharmaceuticals bill under HCPCS A-codes (Lutathera = A9513 + admin CPT 79101), NOT J-codes. ITM-11 uses a no-carrier-added (n.c.a.) 177Lu formulation on a quarterly dosing schedule (4 cycles every 3 months), providing potential site-of-care logistics advantages.
What does the COMPETE Phase 3 trial show for 177Lu-edotreotide?
The regulatory submission for 177Lu-edotreotide is anchored by the international, prospective, randomized, open-label Phase 3 COMPETE trial (NCT03049189). COMPETE evaluated the efficacy and safety of no-carrier-added (n.c.a.) 177Lu-edotreotide compared with oral everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors.
+-----------------------------------------------------------------------------------+
| COMPETE PHASE 3 TRIAL DESIGN |
+-----------------------------------------------------------------------------------+
| Population: 309 adults with progressive, inoperable, SSTR+ G1/G2 GEP-NET |
| Stratification: Target origin (pancreatic NET vs gastrointestinal NET) |
| Randomization: 2:1 ratio (177Lu-edotreotide vs Everolimus) |
| |
| ARM 1: 177Lu-edotreotide (7.5 GBq ± 0.07 GBq IV every 3 months for 4 cycles) |
| Co-administered with amino acid renal protection (L-lysine/L-arginine) |
| ARM 2: Everolimus (10 mg oral once daily continuously until progression) |
+-----------------------------------------------------------------------------------+
Efficacy Endpoints and Statistical Outcomes
COMPETE met its primary endpoint and key secondary endpoints with high statistical significance:
- Primary Endpoint (Progression-Free Survival):
- Median PFS with 177Lu-edotreotide reached 23.9 months compared to 14.1 months with oral everolimus.
- Stratified Hazard Ratio (HR) was 0.67 (95% CI: 0.48–0.95, p = 0.022), demonstrating a 33% reduction in the risk of disease progression or death.
- Overall Response Rate (ORR):
- 177Lu-edotreotide achieved an ORR per blinded independent central review of 21.9% versus 4.2% with everolimus (p < 0.0001), driving substantial objective tumor shrinkage in both pancreatic and gastrointestinal sub-cohorts.
- Safety and Tolerability:
- Treatment-emergent adverse events (TEAEs) were consistent with the established safety profile of peptide receptor radionuclide therapy (PRRT). Grade 3/4 hematologic toxicities (thrombocytopenia, leukopenia) were manageable and transient.
- Renal function remained stable throughout the 4-cycle regimen due to standardized co-infusion of lysine/arginine amino acid renal protective solutions.
How does ITM-11 compare to Lutathera (dotatate)? Is there a head-to-head trial?
When evaluating 177Lu-edotreotide against the established incumbent Lutathera (lutetium Lu 177 dotatate), clinicians and formulary managers must navigate important nuances in trial design, patient populations, radioisotope chemistry, and administration schedules.
Crucial Clinical Fact: There is no head-to-head clinical trial directly comparing 177Lu-edotreotide against Lutathera. Any comparisons are cross-trial observations across separate Phase 3 studies.
+-----------------------------------------------------------------------------------+
| CROSS-TRIAL COMPARISON: COMPETE VS NETTER-1 & NETTER-2 |
+-----------------------------------------------------------------------------------+
| Parameter | COMPETE Trial (ITM-11) | NETTER-1 Trial (Lutathera) |
|---|---|---|
| Trial Population| G1/G2 GEP-NET (Pancreatic & GI) | Midgut NET (G1/G2) |
| Control Arm | Oral Everolimus 10mg daily | High-Dose Octreotide LAR 60mg|
| Median PFS | 23.9 mo vs 14.1 mo (HR 0.67) | 28.4 mo vs 8.5 mo (HR 0.21) |
| ORR (PRRT Arm) | Statistically Superior vs Ev. | 18% vs 3% (p < 0.001) |
| Dosing Interval | Every 3 Months (12 Weeks) x4 | Every 8 Weeks (2 Months) x4 |
| Isotope Type | No-carrier-added (n.c.a. 177Lu) | Carrier-added (c.a. 177Lu) |
+-----------------------------------------------------------------------------------+
1. Comparator Differences: Everolimus vs High-Dose Octreotide
A major distinction between the pivotal trials lies in their control arms:
- Lutathera (NETTER-1): Compared 177Lu-dotatate against high-dose octreotide LAR (60 mg every 4 weeks). Octreotide monotherapy in progressive midgut NET yields a modest baseline median PFS of 8.5 months, resulting in a striking Hazard Ratio of 0.21.
- 177Lu-Edotreotide (COMPETE): Selected an active targeted therapy control arm: oral everolimus (Afinitor, Novartis), an established mTOR inhibitor approved for GEP-NETs with a proven baseline mPFS of 14.1 months in COMPETE. Because everolimus is a more potent active comparator than octreotide, the resulting Hazard Ratio (0.67) reflects a comparison against an active targeted drug floor.
2. Isotope Chemistry: No-Carrier-Added (n.c.a.) vs Carrier-Added 177Lu
A key technical differentiator for ITM-11 is its use of no-carrier-added (n.c.a.) lutetium-177:
- Carrier-Added 177Lu (Lutathera): Produced via neutron irradiation of lutetium-176. This process leaves small amounts of metastable lutetium-177m (177mLu), a long-lived radioactive impurity with a half-life of 160 days. This requires special radioactive waste management and decay handling for site nuclear medicine hot labs.
- No-Carrier-Added 177Lu (ITM-11): Produced via indirect irradiation of ytterbium-176. It yields ultra-pure 177Lu with zero 177mLu impurity. This higher specific activity eliminates long-lived radioactive waste disposal issues for hospitals and reduces non-target radiation exposure.
3. Dosing Schedule and Patient Burden
Administration logistics represent a tangible operational consideration for patients and infusion centers:
- Lutathera: Administered as 7.4 GBq (200 mCi) IV every 8 weeks for 4 cycles (total treatment duration: 24 weeks).
- 177Lu-Edotreotide: Administered as 7.5 GBq IV every 3 months (12 weeks) for 4 cycles (total treatment duration: 36 weeks).
The 3-month quarterly dosing interval of ITM-11 extends the time between infusions, potentially offering lower cumulative visit burden for rural patients traveling to specialized nuclear medicine centers.
For broader context on how radiopharmaceutical pipelines are evolving across oncology, see our survey on radioligand therapy clinical trials 2026.
How is Lu-177 radioligand therapy billed (A-codes) and administered?
A critical point of confusion for healthcare providers, billing departments, and PBM access specialists involves coding mechanics. In biopharma reimbursement, injectable specialty drugs are typically associated with Healthcare Common Procedure Coding System (HCPCS) J-codes (e.g., J9312 for rituximab or J0897 for denosumab).
Therapeutic Radiopharmaceuticals Do Not Use J-Codes.
Therapeutic radiopharmaceuticals are classified by CMS as radiopharmaceutical diagnostic and therapeutic agents and bill under HCPCS A-codes.
+-----------------------------------------------------------------------------------+
| RADIOPHARMACEUTICAL REIMBURSEMENT & CODING MATRIX |
+-----------------------------------------------------------------------------------+
| Product | HCPCS Drug Code (A-Code) | Administration CPT Code |
|---|---|---|
| **Lutathera** | **A9513** | **CPT 79101** |
| (Lu 177 Dotatate)| (Lutetium Lu 177, dotatate, | (Radiopharmaceutical therapy |
| | therapeutic, 1 mCi) | by intravenous administration) |
|---|---|---|
| **177Lu-Edotreotide**| **Pending FDA Approval** | **CPT 79101** |
| (ITM-11) | (Will receive temporary C-code| (Same IV nuclear administration |
| | or permanent A-code) | procedure code) |
|---|---|---|
| **Pluvicto** | **A9607** | **CPT 79101** |
| (Lu 177 PSMA) | (Lutetium Lu 177 vipivotide | (Prostate RLT administration |
| | tetraxetan, therapeutic, 1mCi)| precedent) |
+-----------------------------------------------------------------------------------+
The A9513 Billing Precedent and Per-mCi Pricing
Under Medicare Part B (Outpatient Prospective Payment System - OPPS) and commercial medical benefit billing:
- Drug Unit Billing: Lutathera is billed per millicurie (mCi) using code A9513. A single standard 200 mCi dose is billed as 200 units of A9513.
- Administration Fee: The intravenous infusion procedure is billed separately using CPT 79101 (Radiopharmaceutical therapy, by intravenous administration).
- Renal Protection Co-Infusion: The amino acid infusion (lysine/arginine) administered over 4 hours for renal protection is billed under standard IV infusion CPT codes (e.g., CPT 96365 / 96366) and HCPCS supply codes.
Upon FDA approval, 177Lu-edotreotide will follow this exact billing structure. CMS will assign a unique HCPCS A-code (or a temporary C-code for hospital outpatient pass-through status) per mCi or per dose.
Buy-and-Bill Economics and Pass-Through Status
Radiopharmaceutical therapies carry substantial upfront inventory risk for health systems:
- A single 200 mCi cycle of Lutathera carries a wholesale acquisition cost (WAC) of about $55,896, totaling roughly $224,000 for the full 4-cycle regimen.
- Hospital nuclear medicine departments purchase doses on a just-in-time buy-and-bill basis due to the 6.6-day radioactive half-life of lutetium-177.
- Hospitals rely on Medicare Pass-Through Status under OPPS to receive separate payment outside the Ambulatory Payment Classification (APC) cap during the first 2 to 3 years post-launch.
ITM Radiopharma will apply for Medicare pass-through status immediately upon approval, ensuring that outpatient facilities receive cost-plus reimbursement while the permanent A-code is established.
For deeper analysis of class-wide RLT reimbursement, see our comprehensive radioligand therapy access landscape.
What nuclear medicine site-of-care and radiation safety rules apply?
Because radioligand therapies combine targeted oncology with unsealed radioactive material, site-of-care requirements are far more stringent than standard chemotherapy or infusion biologics.
+-----------------------------------------------------------------------------------+
| SITE-OF-CARE & NUCLEAR MEDICINE IMPLEMENTATION CHECKLIST |
+-----------------------------------------------------------------------------------+
| 1. Radioactive Materials License (RAML): |
| - Site must hold an active NRC or Agreement State license authorized for |
| unsealed 177Lu radiopharmaceutical administration (10 CFR 35.300). |
| |
| 2. Authorized User (AU) Physician: |
| - Administration must be directed by a board-certified Nuclear Medicine |
| physician or Radiation Oncologist designated as an NRC Authorized User. |
| |
| 3. Amino Acid Renal Protection Protocols: |
| - Dedicated IV access line for 4-hour amino acid co-infusion; antiemetic |
| premedication (5-HT3 antagonists) to manage amino-acid-induced nausea. |
| |
| 4. Somatostatin Analogue (SSA) Washout & Coordination: |
| - Discontinue short-acting octreotide 24 hours prior to RLT. |
| - Time long-acting SSAs (Lanreotide/Octreotide LAR) to be administered |
| 4 to 24 hours AFTER the RLT infusion. |
+-----------------------------------------------------------------------------------+
Pre-Requisite Non-Radioactive Therapy: Lanreotide and Octreotide
Before a patient reaches radioligand therapy, consensus clinical guidelines mandate initial control with somatostatin analogues (SSAs) such as lanreotide depot (Somatuline Depot) or octreotide LAR.
Payers enforce a prerequisite step requiring documented disease progression on first-line somatostatin analogue therapy before granting prior authorization for 177Lu radiopharmaceutical therapy. For a detailed breakdown of the generic lanreotide market landscape, see generic lanreotide (Somatuline Depot) market access.
Pre-Launch Payer Preparation Ahead of August 28, 2026
With the PDUFA target date approaching on August 28, 2026, health plan pharmacy directors and medical policy committees are preparing coverage frameworks for 177Lu-edotreotide:
- Diagnostic SSTR Verification: Payers will require positive SSTR PET imaging documentation—using 68Ga-dotatate (Netspot), 68Ga-edotreotide, or 64Cu-dotatate (Detectnet)—confirming intense tracer uptake across all target lesions prior to approving ITM-11.
- Prior Authorization Criteria:
- Confirmed diagnosis of progressive, inoperable, SSTR-positive GEP-NET (G1 or G2).
- Documented disease progression during or following first-line somatostatin analogue therapy (lanreotide or octreotide).
- Maximum authorization: 4 cycles of 7.5 GBq administered every 3 months.
- Formulary Placement: Expected to be placed on the Medical Benefit specialty list with mandatory site-of-care authorization to hospital outpatient nuclear medicine departments or licensed outpatient radiopharmaceutical clinics.
Frequently Asked Questions (FAQs)
Is 177Lu-edotreotide (ITM-11) approved by the FDA yet?
As of August 2026, 177Lu-edotreotide is under active New Drug Application (NDA) review with Fast Track designation by the US FDA. The PDUFA goal date is August 28, 2026. It is not yet commercially available in the US prior to final FDA action.
Will ITM-11 be cheaper than Lutathera, and can they be automatically substituted?
177Lu-edotreotide is a distinct chemical entity (edotreotide peptide chelator vs dotatate peptide chelator) approved under a separate NDA. It is not an interchangeable biosimilar to Lutathera. Pharmacies cannot substitute ITM-11 for Lutathera without a direct physician prescription. Pricing will be established at commercial launch, but ITM Radiopharma is expected to contract competitively against Lutathera ($55,896/dose WAC baseline).
What billing code will hospitals use for ITM-11?
Therapeutic radiopharmaceuticals bill under HCPCS A-codes rather than J-codes. Lutathera uses A9513 per mCi plus CPT 79101 for administration. Upon approval, ITM-11 will receive a dedicated HCPCS A-code (or temporary C-code for hospital outpatient pass-through reimbursement).
Strategic Access Takeaways for 2026
- First Direct Competitor to Lutathera: 177Lu-edotreotide (ITM-11) PDUFA on August 28, 2026 will bring the first direct market alternative to Lutathera in SSTR-positive GEP-NETs.
- Solid Active-Comparator Evidence: COMPETE Phase 3 demonstrated a 23.9-month median PFS versus 14.1 months with oral everolimus (HR 0.67, p=0.022).
- Operational Advantages of No-Carrier-Added 177Lu: Pure n.c.a. 177Lu eliminates long-lived 177mLu radioactive waste, simplifying hot lab management, while the 3-month quarterly dosing schedule reduces patient travel frequency.
- Billing via HCPCS A-Codes: Therapeutic radiopharmaceuticals bill per mCi under A-codes (Lutathera = A9513 + CPT 79101), NOT J-codes. Hospitals will utilize Medicare pass-through status upon ITM-11 approval.
Disclaimer
This article is for informational and educational purposes only and does not constitute clinical, legal, or financial advice. Formulary decisions, prior authorization criteria, and coding rules vary across commercial health plans, Medicare Advantage, and hospital site-of-care contracts. Always consult official FDA prescribing information and payer-specific coverage policies.
Sources
- ITM Isotope Technologies Munich SE. FDA Accepts New Drug Application and Grants PDUFA Date for n.c.a. 177Lu-Edotreotide (ITM-11) in GEP-NETs. November 13, 2025. https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/itm-announces-fda-acceptance-of-new-drug-application-nda-and-pdufa-date-for-n-c-a-177lu-edotreotide-itm-11-in-gastroenteropancreatic-neuroendocrine-tumors-gep-nets-747
- OncLive. FDA Accepts NDA for 177Lu-Edotreotide for GEP-NETs. November 2025. https://www.onclive.com/view/fda-accepts-nda-for-177lu-edotreotide-for-gep-nets
- U.S. Food and Drug Administration (FDA). FDA Approves Lutetium Lu 177 Dotatate for GEP-NETs (Lutathera approval notice, NDA 208700). January 26, 2018. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-dotatate-treatment-gep-nets
- Strosberg JR, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1). N Engl J Med. 2017;376(2):125-135. https://www.nejm.org/doi/full/10.1056/NEJMoa1607427
- U.S. Food and Drug Administration (FDA). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. July 2026. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
- Centers for Medicare & Medicaid Services (CMS). Healthcare Common Procedure Coding System (HCPCS) Quarterly Update. July 2026. https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-coding-system-hcpcs-level-ii
- Infectious Disease Advisor. FDA Drug Approval Decisions Expected in August 2026. July 2026. https://www.infectiousdiseaseadvisor.com/news/fda-drug-approval-decisions-expected-in-august-2026
